Square Pharmaceuticals (DHA:SQURPHARMA) Debt-to-Equity : 0.01 (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Square Pharmaceuticals Debt-to-Equity?

Square Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was BDT599 Mil. Square Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was BDT949 Mil. Square Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was BDT121,787 Mil. Square Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Square Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

DHA:SQURPHARMA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.06
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Square Pharmaceuticals was 0.06. The lowest was 0.00. And the median was 0.02.

DHA:SQURPHARMA's Debt-to-Equity is ranked better than
99.88% of 853 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs DHA:SQURPHARMA: 0.01

Square Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Square Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Square Pharmaceuticals Debt-to-Equity Chart

Square Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

Square Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.02	0.02	0.01	0.01

Competitive Comparison of Square Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Square Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Square Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Square Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Square Pharmaceuticals's Debt-to-Equity falls into.

Square Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Square Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(618.609	+	1368.357)	/	115195.939
	=	0.02

Square Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(599.116	+	948.895)	/	121786.897
	=	0.01

Square Pharmaceuticals (DHA:SQURPHARMA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Square Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Square Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Square Pharmaceuticals (DHA:SQURPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Square Pharmaceuticals PLC (DHA:SQURPHARMA) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

Square Centre, 48, Mohakhali Commercial Area, Dhaka, BGD, 1212

Website

http://www.squarepharma.com.bd

Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceuticals products, Basic chemical products, and animal health products. It manufactures drugs like paracetamol, clotrimazole, antiallergic, Nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs. The company operates in Bangladesh and sells its products locally and internationally. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs.

Square Pharmaceuticals (DHA:SQURPHARMA) Headlines

No Headlines